Showing results (1061-1070 of 2,811) with videos related to
Sort By:
Pageof 282
Expert Opinion on Drug Safety|August 10, 2020
Possible effects of excipients used in the parenteral drugs administered in critically ill adults, children, and neonatesKannan Sridharan, Hasan Msn Hasan, Muna Al Jufairi, et al.Expert Opinion on Drug Safety|April 1, 2021
A reappraisal of the role of fever in the occurrence of neurological sequelae following lithium intoxication: a systematic reviewHélène Verdoux, Anne-Laure Debruyne, Emmanuelle Queuille, et al.Expert Opinion on Drug Safety|August 4, 2020
Safety of pembrolizumab in recurrent or advanced gastric cancer expressing PD-L1 refractory to platinum and fluoropyrimidineSaori Mishima, Akihito Kawazoe, Kohei ShitaraExpert Opinion on Drug Safety|August 7, 2020
Interventions to improve spontaneous adverse drug reaction reporting by healthcare professionals and patients: systematic review and meta-analysisVibhu Paudyal, Abdullah Al-Hamid, Matthew Bowen, et al.Expert Opinion on Drug Safety|July 14, 2020
A drug safety evaluation of atezolizumab in locally advanced or metastatic urothelial carcinomaPanagiota Economopoulou, Ioannis Kotsantis, Aristotelis BamiasExpert Opinion on Drug Safety|August 18, 2020
Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysisFrancesco Massari, Veronica Mollica, Alessandro Rizzo, et al.Expert Opinion on Drug Safety|April 26, 2021
Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinionJanny E Lommerts, Marcel W Bekkenk, Rosalie M LuitenExpert Opinion on Drug Safety|April 18, 2023
PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS)Qiaoyun Wang, Fengjiao Xiao, Yanbin Zeng, et al.Expert Opinion on Drug Safety|April 12, 2021
Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EUDianne Butler, Katarina Vucic, Sabine Straus, et al.Expert Opinion on Drug Safety|April 19, 2021
Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphomaAnna Candoni, Davide Lazzarotto, Giuseppe PetruzzellisPageof 282